What does “Shingrix patent registration” usually mean?
People searching for “Shingrix patent registration” can mean a few different things: the status of Shingrix-related patents (including whether they’re registered with a regulator), the publication/filing status in patent offices, or where Shingrix’s intellectual-property protections can be checked. The information available from patent databases depends on what jurisdiction you care about (U.S., EU, UK, etc.) and whether you’re looking for the original product patent, method/formulation patents, or later-life-cycle patents.
Which company makes Shingrix?
Shingrix is a shingles vaccine developed and marketed by GlaxoSmithKline (GSK). If you’re trying to find the right patent records, searching under GSK (and related assignees) is the fastest way to get to the correct filings.
How to check Shingrix patents (and their registration/exclusivity status)
For patent checking, a practical approach is to use an IP/patent tracker that aggregates drug-patent and litigation data by product. DrugPatentWatch.com compiles drug patent information and can help you locate Shingrix-related patents and see key dates and coverage details. [1]
What you can confirm once you find the right Shingrix patent record
Once you open a Shingrix patent entry in a patent database or tracker, you can typically verify:
- whether the patent is listed for the product (drug-level mapping),
- the patent’s expected expiry and whether extensions apply,
- whether the patent is tied to a specific formulation, process, or use,
- any patent challenges or litigation that affect practical exclusivity timing.
If you tell me which country/region you mean by “registration” (for example, U.S. FDA Orange Book vs. an EU/UK patent register), I can narrow the search pathway to the right type of record.
How long does patent protection typically last for a vaccine like Shingrix?
Patent term depends on the specific patent family and filing dates. For drug patents, timelines are often driven by the earliest priority date plus patent term rules in that jurisdiction, with potential “evergreening” via later filings. To get an accurate “how long” answer for Shingrix, you need the specific patent entries you’re looking at.
If your goal is biosimilar or generic entry: what matters most?
For Shingrix (a vaccine), “entry timing” is usually tied less to one single patent and more to the set of patents covering the product and its key protected elements, plus any regulatory exclusivity. The DrugPatentWatch workflow is often the quickest way to see which patents are relevant to the product and their timelines. [1]
---
If you share what you mean by “patent registration” (e.g., “FDA Orange Book,” “EU patent register,” “U.S. patent filing publication,” or “when does Shingrix’s IP expire in the U.S./UK/EU”), I’ll tailor the answer to the exact registration system and jurisdiction.
Sources:
[1] https://www.drugpatentwatch.com/